Supply and Clinical Application of Actinium-225 and Bismuth-213
Aliyah Morgenstern, Christos Apostolidis, Frank Bruchertseifer
Abstract
The recent development of 225Ac-PSMA617 for therapy of prostate cancer has strikingly demonstrated the clinical potential of targeted alpha therapy. Further promising applications of the alpha emitters 225Actinium and its daughter nuclide 213Bismuth include the therapy of brain tumors, bladder cancer, neuroendocrine tumors, and leukemia. This paper will provide a brief overview on the current status of the clinical development of compounds labelled with 225Ac or 213Bi and describe the various production routes that are in place or are under development to meet the increasing demand for these radionuclides.
Topics & Concepts
MedicineProstate cancerRadionuclide therapyCancerRadiation therapyOncologyAlpha (finance)Cancer therapyCancer researchInternal medicineSurgeryPatient satisfactionConstruct validityRadiopharmaceutical Chemistry and ApplicationsProstate Cancer Treatment and ResearchMedical Imaging Techniques and Applications